anti-Peptidyl Arginine Deiminase, Type II (PADI2) Antibodies

PADI2 encodes a member of the peptidyl arginine deiminase family of enzymes, which catalyze the post-translational deimination of proteins by converting arginine residues into citrullines in the presence of calcium ions. Additionally we are shipping Peptidyl Arginine Deiminase, Type II Kits (16) and Peptidyl Arginine Deiminase, Type II Proteins (14) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
PADI2 11240 Q9Y2J8
PADI2 18600 Q08642
PADI2 29511 P20717
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-Peptidyl Arginine Deiminase, Type II Antibodies at antibodies-online.com

Showing 10 out of 84 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Delivery Price Details
Cow Rabbit Un-conjugated WB WB Suggested Anti-PADI2 Antibody Titration: 0.2-1 ug/mlPositive Control: Jurkat cell lysate 100 μL 2 to 3 Days
$319.00
Details
Human Rabbit Un-conjugated WB PADI2 Antibody (C-term) (ABIN658290) western blot analysis in MDA-MB231 cell line lysates (35 µg/lane). This demonstrates the PADI2 antibody detected the PADI2 protein (arrow). 400 μL 10 to 11 Days
$385.00
Details
Cow Rabbit Un-conjugated WB 100 μL 11 to 14 Days
$581.17
Details
Human Rabbit Un-conjugated IHC, WB ABIN6272859 at 1/100 staining Mouse spleen tissue by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The sample was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. Western blot analysis of extracts of BxPC-3 cells, using PADI2 antibody. 100 μL 11 to 12 Days
$390.77
Details
Human Rabbit Un-conjugated ICC, IHC, WB Western Blot; Sample: Rat Cerebrum lysate; Primary Ab: 3µg/ml Rabbit Anti-Human PADI2 Antibody Second Ab: 0.2µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19) Figure. Western Blot; Sample: Recombinant protein. 100 μg 13 to 16 Days
$350.00
Details
Human Rabbit Un-conjugated ELISA, WB 100 μL 2 to 3 Days
$446.88
Details
Human Rabbit Un-conjugated WB PADI2 antibody used at 0.5 ug/ml to detect target protein. 50 μg 9 to 11 Days
$449.29
Details
Human Mouse Un-conjugated ELISA, WB Detection limit for recombinant GST tagged PADI2 is approximately 0.3ng/ml as a capture antibody. Western Blot detection against Immunogen (37.62 KDa) . 100 μg 11 to 12 Days
$440.00
Details
Human Rabbit Un-conjugated ELISA, WB   100 μg 11 to 14 Days
$449.17
Details
Human Mouse Un-conjugated ELISA, WB Western Blot detection against Immunogen (37.99 KDa) . 50 μL 11 to 12 Days
$305.71
Details

Top referenced anti-Peptidyl Arginine Deiminase, Type II Antibodies

  1. Human Monoclonal PADI2 Primary Antibody for ELISA, WB - ABIN564891 : Blachère, Parveen, Fak, Frank, Orange: Inflammatory but not apoptotic death of granulocytes citrullinates fibrinogen. in Arthritis research & therapy 2015 (PubMed)

More Antibodies against Peptidyl Arginine Deiminase, Type II Interaction Partners

Human Peptidyl Arginine Deiminase, Type II (PADI2) interaction partners

  1. Chronic gingival inflammation is associated with increased local citrullination and PAD2 and PAD4 expression in periodontitis.

  2. In most rheumatoid arthritis patients, PAD2 and PAD4 are equally efficient in generating citrullinated target sites for anti-citrullinated protein antibodies (ACPAs) in fibrinogen and ENO1. The binding of autoantibodies to histone H3 was generally higher after citrullination with PAD4 than with PAD2. Citrullinated human serum albumin is not a target for ACPAs.

  3. the mRNA expression of PADI2, PADI4 and Sp1 is upregulated in rheumatoid arthritis bone marrow CD34+ cells independently of the systemic inflammation or treatment regimen.

  4. These data suggest that overexpression of the human PAD2 transgene in the epidermis of transgenic mice increases the malignant conversion rate of benign tumors by promoting an inflammatory microenvironment.

  5. Brain gene expression of PADI2, ZNF385A, PSD2, and A2ML1 and DNA methylation dysregulations are implicated in the alteration of brain tissue properties associated with late-life cognitive decline above and beyond the influence of common neuropathologic conditions.

  6. Peptidyl arginine deiminase 2 (PADI2) is required for activation of androgen receptor (AR) signaling under androgen-deprived condition.

  7. Data suggest that protein-arginine deiminase 2 (PADI2) suppresses the proliferation of colonic epithelial cells through catalysis of protein citrullination, and that downregulation of PADI2 expression might therefore contribute to colon carcinogenesis.

  8. Downregulation of PADI2 is an early event in the pathogenesis of colorectal cancer associated with poor prognosis and points toward a possible role of citrullination in modulating tumor cells and their microenvironment.

  9. Multiple proteins citrullinated by hypoxia-induced PADs were identified. In addition, the extracellular domain of vascular endothelial growth factor receptor 2 was citrullinated by human PAD2 in vitro. CONCLUSION: Our data may contribute to understanding of pathophysiology of malignant gliomas from the aspects of protein citrullination.

  10. Deimination of myelin basic protein (MBP) by peptidylarginine deiminase (PAD) prevents its binding to the proteasome and decelerates its degradation by the proteasome in mammalian cells. Potential anticancer drug tetrazole analogue of chloramidine 2, at concentrations greater than 1 microM inhibits the enzymatic activity of PAD in vitro.

  11. this study shows that a miR-4728 downregulates PADI2, a novel rheumatoid arthritis risk gene

  12. We identified the presence of PADI3 mRNA expression in synovial tissue and PADI2 and PADI4 mRNA expressions in fibroblast-like synoviocytes from patients with rheumatoid arthritis.

  13. Protein arginine deiminase 2 binds six calcium ions in an ordered fashion.

  14. PAD2 activity was significantly higher in cell-free synovial fluid of rheumatoid arthritis patients compared to osteoarthritis patients.

  15. PAD2 activity was detected in synovial fluid samples from patients with rheumatoid arthritis.

  16. Report increased levels of extracellular PAD2 in the lungs of smokers.

  17. PADI2 and vimentin participate in the apoptotic mechanisms of activated T lymphocytes.

  18. these studies provide the first genetic evidence that PAD2 functions as an oncogene and suggest that PAD2 may promote tumor progression by enhancing inflammation within the tumor microenvironment.

  19. PAD2 appears to use a substrate-assisted mechanism of catalysis in which the positively charged substrate guanidinium depresses the pKa of the nucleophilic cysteine

  20. Data suggest peptidylarginine deiminase 2 (PAD2) as a possible biomarker in various inflammatory diseases.

Cow (Bovine) Peptidyl Arginine Deiminase, Type II (PADI2) interaction partners

  1. results describe the role of peptidyl arginine deiminase and arginine metabolism in the formation of amyloid fibrils from beta-amyloid peptides

Mouse (Murine) Peptidyl Arginine Deiminase, Type II (PADI2) interaction partners

  1. PADi2 contributes to TNFalpha-induced citrullination and arthritis, but is not required for neutrophil extracellular traps formation

  2. Taken together, our study is the first to indicate the potential role of Padi2 as an angiogenesis-regulating gene. The characterization of Padi2 and other genes in associated pathways may provide new understanding of angiogenesis regulation and novel targets for diagnosis and treatment of a wide variety of angiogenesis-dependent diseases.

  3. peptidyl-arginine deiminases inhibiion reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis.

  4. GPx7 is an unusual CysGPx catalyzing the peroxidatic cycle by a one Cys mechanism in which GSH and PDI are alternative substrates.

  5. Results suggest that PADI2 may function as an important new biomarker for HER2/ERBB2+ tumors and that Cl-amidine represents a new candidate for breast cancer therapy.

  6. Activation of the P2X7 purinergic receptor (P2X7) by the inflammatory danger signal ATP induces PAD2 activity and robust protein citrullination in mast cells.

  7. different subcellular compartmentalization of PADi2 and citrullinated proteins may have different physiological roles in normal and neurodegenerative conditions

  8. PAD2 interacts with IKKgamma and suppresses NF-kappaB activity.

  9. Results suggest that peptidylarginine deiminase 2-catalyzed citrullination is not essential to the development of experimental autoimmune encephalomyelitis.

  10. An increase in citrullinated proteins resulting from increased PAD2 and 4 is an important change in the pathogenesis of multiple sclerosis.

  11. This study suggests that accumulated citrullinated proteins and abnormal activation of PAD2 may function in the pathogenesis of prion diseases and serve as potential therapeutic targets.

  12. elevated levels of the pro-inflammatory cytokine TNF-alpha and nuclear histone deimination support initiation of demyelination by increased PAD activity

Peptidyl Arginine Deiminase, Type II (PADI2) Antigen Profile

Protein Summary

This gene encodes a member of the peptidyl arginine deiminase family of enzymes, which catalyze the post-translational deimination of proteins by converting arginine residues into citrullines in the presence of calcium ions. The family members have distinct substrate specificities and tissue-specific expression patterns. The type II enzyme is the most widely expressed family member. Known substrates for this enzyme include myelin basic protein in the central nervous system and vimentin in skeletal muscle and macrophages. This enzyme is thought to play a role in the onset and progression of neurodegenerative human disorders, including Alzheimer disease and multiple sclerosis, and it has also been implicated in glaucoma pathogenesis. This gene exists in a cluster with four other paralogous genes.

Gene names and symbols associated with PADI2

  • peptidyl arginine deiminase 2 (PADI2) antibody
  • peptidyl arginine deiminase, type II (padi2) antibody
  • protein-arginine deiminase type-2 (LOC100357368) antibody
  • peptidyl arginine deiminase, type II S homeolog (padi2.S) antibody
  • peptidyl arginine deiminase, type II (PADI2) antibody
  • peptidyl arginine deiminase, type II (Padi2) antibody
  • peptidyl arginine deiminase 2 (Padi2) antibody
  • mKIAA0994 antibody
  • PAD-H19 antibody
  • PAD2 antibody
  • PADI2 antibody
  • Pdi antibody
  • Pdi2 antibody

Protein level used designations for PADI2

peptidyl arginine deiminase, type II , protein-arginine deiminase type-2-like , peptidlyarginine deiminase type II , peptidylarginine deiminase II , protein arginine deiminase , protein-arginine deiminase type II , protein-arginine deiminase type-2 , peptidyl arginine deiminase, type 2 , PAD type II , peptidyl arginine deiminase, type II; PAD type II

GENE ID SPECIES
456527 Pan troglodytes
711044 Macaca mulatta
100050025 Equus caballus
100125112 Xenopus (Silurana) tropicalis
100357368 Oryctolagus cuniculus
100437331 Pongo abelii
100473552 Ailuropoda melanoleuca
11240 Homo sapiens
380061 Xenopus laevis
428172 Gallus gallus
617851 Bos taurus
18600 Mus musculus
29511 Rattus norvegicus
487414 Canis lupus familiaris
100621356 Sus scrofa
Selected quality suppliers for anti-Peptidyl Arginine Deiminase, Type II (PADI2) Antibodies
Did you look for something else?